Monitoring Report: Respiratory Viruses – December 2025 Data

Samuel Gratzl*, PhD

Karen Gilbert Farrar*, PhD

Duy Do, PhD

Nina Masters, MPH, PhD

Brianna M Goodwin Cartwright, MS

* Denotes co-first author

Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:
Brianna M Goodwin Cartwright
Truveta, Inc
1745 114th Ave SE, Bellevue, WA 98004
Email: briannac@truveta.com

Abstract

Background: Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.

Objective: This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through January 04, 2026) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2020 and January 04, 2026. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.

Results: We included 1,010,216 hospitalizations of 885,367 unique patients who tested positive for a respiratory virus between October 01, 2020 and January 04, 2026.

Overall, respiratory virus associated hospitalizations increased substantially throughout December 2025. By the last week of the month, respiratory virus-associated hospitalizations accounted for 6.9% of all hospitalizations, up from 3.0% at the beginning of December (+125.3%). This increase was driven primarily by influenza, with influenza-associated hospitalizations rising sharply (+277.1%). COVID and RSV-associated hospitalizations also increased (+61.8% and +83.7%, respectively), while rhinovirus-associated hospitalizations declined slightly.

Among children aged 0–4 years, respiratory virus-associated hospitalizations remained largely stable across December and accounted for 3.6% of all hospitalizations by the end of the month (−7.2%). This stability reflected increasing influenza-associated hospitalizations (+44.6%) offset by declines in rhinovirus-, COVID-, and parainfluenza-associated hospitalizations. RSV-associated hospitalizations remained stable and continued to represent the largest share of respiratory virus associated hospitalizations in this age group (1.7%). Among adults aged 65 years and older, respiratory virus-associated hospitalizations increased substantially across December, reaching 9.4% of all hospitalizations by the last week of the month (+154.1%). Influenza-associated hospitalizations increased more than fourfold (+316.1%) and were

the primary driver of this increase. COVID-, RSV-, and HMPV-associated hospitalizations also rose.

Discussion: Respiratory virus–associated hospitalizations increased substantially overall during December 2025, accounting for nearly 7% of all hospitalizations. In the pediatric population, hospitalization rates remained relatively stable, as increases in influenza-associated hospitalizations were offset by declines in rhinovirus-, COVID-, and parainfluenza-associated hospitalizations, while RSV remained the leading cause of respiratory virus-associated hospitalizations in this age group. Among older adults, respiratory virus-associated hospitalizations rose sharply, driven primarily by a marked increase in influenza-associated hospitalizations, with additional increases observed for COVID-, RSV-, and HMPV-. Together, these patterns highlight influenza as the dominant contributor to rising respiratory hospitalization burden in December and underscore the importance of continued surveillance as seasonal respiratory virus activity intensifies, particularly among older adults at higher risk for severe outcomes.

Trends in surveillance

Overall population



Date	Overall	COVID	Influenza	HMPV	parainfluenza	RSV	rhinovirus
December 01, 2025	3.0%	0.6%	1.1%	0.1%	0.2%	0.4%	1.0%
December 29, 2025	6.9%	1.0%	4.2%	0.2%	0.2%	0.7%	0.8%
Change (percentage)	+125.3%	+61.8%	+277.1%	+161.6%	-13.7%	+83.7%	-19.3%
Difference (percentage points)	+3.8%	+0.4%	+3.1%	+0.1%	-0.0%	+0.3%	-0.2%



Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
December 01, 2025	6.5%	3.6%	9.8%	1.3%	3.5%	4.2%	16.0%
December 29, 2025	11.0%	5.0%	18.8%	2.8%	2.3%	5.2%	10.7%
Change (percentage)	+68.1%	+37.4%	+92.9%	+108.7%	-34.3%	+22.5%	-32.9%
Difference (percentage points)	+4.5%	+1.4%	+9.1%	+1.4%	-1.2%	+1.0%	-5.3%

At the end of December 2025, respiratory virus-associated hospitalizations accounted for 6.9% of all hospitalizations, more than double the proportion at the beginning of December (3.0%, +125.3%). Influenza-associated hospitalizations increased from 1.1% to 4.2% of all hospitalizations (+277.1%), COVID-associated hospitalizations increased from 0.6% to 1.0% of all hospitalizations (+61.8%), RSV-associated hospitalizations increased from 0.4% to 0.7% of all hospitalizations (+83.7%), and rhinovirus-associated hospitalizations decreased slightly from 1.0% to 0.8% of all hospitalizations (-19.3%). HMPV-, parainfluenza-associated hospitalizations all remained relatively low and stable across the month.

Influenza, COVID, and HMPV test positivity increased notably (+92.9%, +37.4%, and +108.7%, respectively), while RSV test positivity increased slightly (+22.5%). Rhinovirus and parainfluenza test positivity decreased (-32.9% and -34.3%, respectively).

The increases in respiratory virus-associated hospitalizations and test positivity indicate a clear seasonal escalation. Influenza was the primary driver, accounting for the largest rise in associated hospitalizations.

Infants and children (age 0-4)





Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
December 01, 2025	3.9%	0.6%	0.8%	0.2%	0.3%	1.6%	1.7%
December 29, 2025	3.6%	0.4%	1.2%	0.2%	0.1%	1.7%	0.8%
Change (percentage)	-7.2%	-29.5%	+44.6%	+47.9%	-75.4%	+1.8%	-54.0%
Difference (percentage points)	-0.3%	-0.2%	+0.4%	+0.1%	-0.2%	+0.0%	-0.9%





Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
December 01, 2025	11.5%	3.8%	12.1%	3.6%	10.1%	14.5%	35.4%
December 29, 2025	16.1%	4.9%	23.9%	6.1%	5.8%	17.0%	24.5%
Change (percentage)	+40.7%	+31.4%	+97.2%	+66.6%	-43.0%	+17.1%	-30.9%
Difference (percentage points)	+4.7%	+1.2%	+11.8%	+2.4%	-4.4%	+2.5%	-10.9%

In the population aged 0–4 years, respiratory virus-associated hospitalizations remained stable throughout December and are now at a rate of 3.6% of all hospitalizations in this age group (-7.2%). This stability reflects opposing trends, with influenza-associated hospitalizations increasing from 0.8% to 1.2% of all

hospitalizations (+44.6%), offset by declines in rhinovirus-, COVID-, and parainfluenza-associated hospitalizations (−54.0%, −29.5%, and -75.4% respectively). RSV-associated hospitalizations were stable overall, despite a brief increase observed in mid-December, and accounted for 1.7% of all hospitalizations by the end of the month, representing the largest share of respiratory virus-associated hospitalizations in this age group. HMPV-associated hospitalizations remained low and unchanged across the month (0.2%).

In this pediatric population, influenza, HMPV, and COVID test positivity increased substantially (+97.2%, +66.6%, +31.4%, respectively), while RSV test positivity increased slightly (+17.1%). Rhinovirus and parainfluenza test positivity decreased (-30.9% and -43.0%, respectively). Together, these patterns indicate a shift in the respiratory virus landscape among children aged 0 to 4 years, with increasing influenza-associated hospitalizations alongside declines in rhinovirus-, COVID-, and parainfluenza-associated hospitalizations.

Older adults (age 65 and over)



Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
December 01, 2025	3.7%	0.9%	1.4%	0.1%	0.2%	0.3%	1.1%
December 29, 2025	9.4%	1.5%	5.9%	0.3%	0.2%	0.8%	0.9%
Change (percentage)	+154.1%	+66.4%	+316.1%	+157.5%	-6.6%	+155.0%	-10.3%
Difference (percentage points)	+5.7%	+0.6%	+4.5%	+0.2%	-0.0%	+0.5%	-0.1%



Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
December 01, 2025	4.1%	4.0%	5.4%	0.9%	1.9%	1.6%	9.8%
December 29, 2025	8.2%	5.6%	14.5%	2.2%	1.8%	2.8%	7.9%
Change (percentage)	+101.4%	+38.1%	+169.0%	+133.9%	-2.9%	+70.2%	-19.0%
Difference (percentage points)	+4.1%	+1.5%	+9.1%	+1.2%	-0.1%	+1.1%	-1.9%

Among adults aged 65 years and older, respiratory virus–associated hospitalizations increased substantially across December and accounted for 9.4% of all hospitalizations in the last week of December 2025, an increase from 3.7% at the beginning of the month (+154.1%). Influenza-associated hospitalizations increased more than fourfold (+316.1%), rising to 5.9% of all hospitalizations in this age group. COVID-, RSV-, and HMPV-associated hospitalizations also increased across December (+66.4%, +155.0%, and +157.5%, respectively). Rhinovirus-associated hospitalizations decreased slightly to 0.9% of all hospitalizations, while parainfluenza-associated hospitalizations remained low and relatively stable across the month.

In this older adult population, influenza test positivity increased sharply (+169.0%). COVID, RSV, and HMPV test positivity increased across the month (+38.1%, +70.2%, and +133.9%, respectively). Parainfluenza test positivity remained stable, while rhinovirus positivity decreased slightly (-19.0 %). Overall, these findings indicate a substantial increase in respiratory virus associated hospitalizations among older adults across December, driven primarily by influenza, with additional increases also observed for COVID, RSV, and HMPV.

Introduction

COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses

known to cause respiratory illness such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death especially in vulnerable populations, such as infants, children, and older adults (Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.

Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions such as chronic lung diseases and asthma.

Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.

This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.

Methods

Data

We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV),

parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2020 and January 04, 2026 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on January 14, 2026 and included de-identified patient care data primarily located across ten states: California, Florida, Texas, New York, Virginia, Illinois, Washington, Ohio, Michigan, and Arizona.

Population

We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.

Hospitalization rate analysis

Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Test positivity rate analysis

Lab results with known results were summarized over time by virus. The positivity rate was calculated monthly as the number of positive lab results divided by the total number of lab results with known results in that month.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Results

Overall population

Our study population consists of 1,010,216 hospitalizations of 885,367 unique patients (Table 1).

Table 1: Patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	208,130 (100.00%)	219,484 (100.00%)	155,018 (100.00%)	149,774 (100.00%)	127,310 (100.00%)	25,651 (100.00%)	885,367 (100.00%)
Age Group							
< 6 months	1,805 (0.87%)	3,207 (1.46%)	4,225 (2.73%)	3,388 (2.26%)	2,622 (2.06%)	586 (2.28%)	15,833 (1.79%)
6 - <12 months	803 (0.39%)	1,545 (0.70%)	2,076 (1.34%)	1,814 (1.21%)	1,601 (1.26%)	338 (1.32%)	8,177 (0.92%)
1 - <2 years	1,311 (0.63%)	2,200 (1.00%)	2,810 (1.81%)	2,376 (1.59%)	2,495 (1.96%)	684 (2.67%)	11,876 (1.34%)
2 - 4 years	1,423 (0.68%)	3,254 (1.48%)	4,095 (2.64%)	2,985 (1.99%)	3,189 (2.50%)	826 (3.22%)	15,772 (1.78%)
5 - 17 years	2,468 (1.19%)	4,118 (1.88%)	4,690 (3.03%)	4,230 (2.82%)	4,297 (3.38%)	1,107 (4.32%)	20,910 (2.36%)
18 - 49 years	49,141 (23.61%)	47,298 (21.55%)	22,341 (14.41%)	21,060 (14.06%)	18,743 (14.72%)	3,948 (15.39%)	162,531 (18.36%)
50 - 64 years	53,760 (25.83%)	46,091 (21.00%)	25,308 (16.33%)	24,995 (16.69%)	21,904 (17.21%)	4,051 (15.79%)	176,109 (19.89%)
65 - 74 years	42,663 (20.50%)	44,026 (20.06%)	30,356 (19.58%)	30,282 (20.22%)	25,675 (20.17%)	4,965 (19.36%)	177,967 (20.10%)
75 - 84 years	35,279 (16.95%)	41,754 (19.02%)	34,885 (22.50%)	35,151 (23.47%)	28,683 (22.53%)	5,572 (21.72%)	181,324 (20.48%)
85+ years	19,477 (9.36%)	25,991 (11.84%)	24,232 (15.63%)	23,493 (15.69%)	18,101 (14.22%)	3,574 (13.93%)	114,868 (12.97%)
Sex							
Female	102,490 (49.24%)	113,141 (51.55%)	81,505 (52.58%)	78,797 (52.61%)	67,501 (53.02%)	13,665 (53.27%)	457,099 (51.63%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Male	104,947 (50.42%)	105,575 (48.10%)	72,933 (47.05%)	70,356 (46.97%)	59,349 (46.62%)	11,781 (45.93%)	424,941 (48.00%)
Other	3 (0.00%)	2 (0.00%)	4 (0.00%)	1 (0.00%)	1 (0.00%)	0	11 (0.00%)
Unknown	690 (0.33%)	766 (0.35%)	576 (0.37%)	620 (0.41%)	459 (0.36%)	205 (0.80%)	3,316 (0.37%)
Race							
White	133,983 (64.37%)	147,860 (67.37%)	102,987 (66.44%)	98,154 (65.53%)	83,734 (65.77%)	16,321 (63.63%)	583,039 (65.85%)
Black or African American	31,851 (15.30%)	31,473 (14.34%)	21,483 (13.86%)	22,250 (14.86%)	18,452 (14.49%)	4,367 (17.02%)	129,876 (14.67%)
Asian	4,836 (2.32%)	4,799 (2.19%)	4,536 (2.93%)	3,970 (2.65%)	3,427 (2.69%)	752 (2.93%)	22,320 (2.52%)
Native Hawaiian or Other Pacific Islander	973 (0.47%)	1,010 (0.46%)	750 (0.48%)	755 (0.50%)	712 (0.56%)	161 (0.63%)	4,361 (0.49%)
American Indian or Alaska Native	1,202 (0.58%)	1,309 (0.60%)	942 (0.61%)	794 (0.53%)	714 (0.56%)	142 (0.55%)	5,103 (0.58%)
Other Race	13,748 (6.61%)	11,669 (5.32%)	9,464 (6.11%)	9,061 (6.05%)	8,733 (6.86%)	1,690 (6.59%)	54,365 (6.14%)
Unknown	21,537 (10.35%)	21,364 (9.73%)	14,856 (9.58%)	14,790 (9.87%)	11,538 (9.06%)	2,218 (8.65%)	86,303 (9.75%)
Ethnicity							
Hispanic or Latino	24,694 (11.86%)	19,694 (8.97%)	15,049 (9.71%)	15,569 (10.39%)	15,406 (12.10%)	3,184 (12.41%)	93,596 (10.57%)
Not Hispanic or Latino	161,435 (77.56%)	179,288 (81.69%)	126,205 (81.41%)	121,603 (81.19%)	102,921 (80.84%)	20,928 (81.59%)	712,380 (80.46%)
Unknown	22,001 (10.57%)	20,502 (9.34%)	13,764 (8.88%)	12,602 (8.41%)	8,983 (7.06%)	1,539 (6.00%)	79,391 (8.97%)
Virus							
COVID	190,081 (91.33%)	186,023 (84.75%)	86,775 (55.98%)	74,716 (49.89%)	37,831 (29.72%)	5,428 (21.16%)	580,854 (65.61%)
HMPV	98 (0.05%)	2,939 (1.34%)	4,913 (3.17%)	4,294 (2.87%)	5,439 (4.27%)	612 (2.39%)	18,295 (2.07%)
RSV	2,336 (1.12%)	4,937 (2.25%)	9,363 (6.04%)	11,538 (7.70%)	12,252 (9.62%)	2,000 (7.80%)	42,426 (4.79%)
influenza	7,274 (3.49%)	13,697 (6.24%)	34,011 (21.94%)	36,988 (24.70%)	43,923 (34.50%)	8,710 (33.96%)	144,603 (16.33%)
parainfluenza	1,499 (0.72%)	2,411 (1.10%)	4,575 (2.95%)	4,909 (3.28%)	5,412 (4.25%)	1,292 (5.04%)	20,098 (2.27%)
rhinovirus	6,842 (3.29%)	9,477 (4.32%)	15,381 (9.92%)	17,329 (11.57%)	22,453 (17.64%)	7,609 (29.66%)	79,091 (8.93%)
Comorbidity							
Asthma	18,002 (8.65%)	22,059 (10.05%)	19,083 (12.31%)	20,114 (13.43%)	19,292 (15.15%)	4,179 (16.29%)	102,729 (11.60%)
Chronic Lung Disease	12,769 (6.14%)	14,352 (6.54%)	11,539 (7.44%)	11,886 (7.94%)	11,684 (9.18%)	2,319 (9.04%)	64,549 (7.29%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Chronic Obstructive Pulmonary Disease	23,323 (11.21%)	32,849 (14.97%)	27,755 (17.90%)	29,085 (19.42%)	25,990 (20.41%)	5,115 (19.94%)	144,117 (16.28%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.

Figure 1: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020



Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020



Test positivity rate over time

We included 75,673,121 lab results with known results of which 7,133,141 were positive. The test positivity rate is shown in Figure 3.

Figure 3: Weekly test positivity rate since October 2020



COVID-19

Our COVID study population consists of 604,858 hospitalizations of 580,854 unique patients (Table 2).

Table 2: COVID patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	190,081 (100.00%)	186,023 (100.00%)	86,775 (100.00%)	74,716 (100.00%)	37,831 (100.00%)	5,428 (100.00%)	580,854 (100.00%)
Age Group							
< 6 months	342 (0.18%)	858 (0.46%)	423 (0.49%)	441 (0.59%)	403 (1.07%)	65 (1.20%)	2,532 (0.44%)
6 - <12 months	62 (0.03%)	272 (0.15%)	186 (0.21%)	219 (0.29%)	244 (0.64%)	32 (0.59%)	1,015 (0.17%)
1 - <2 years	96 (0.05%)	252 (0.14%)	136 (0.16%)	269 (0.36%)	462 (1.22%)	84 (1.55%)	1,299 (0.22%)
2 - 4 years	141 (0.07%)	363 (0.20%)	124 (0.14%)	266 (0.36%)	620 (1.64%)	136 (2.51%)	1,650 (0.28%)
5 - 17 years	1,163 (0.61%)	1,682 (0.90%)	560 (0.65%)	619 (0.83%)	984 (2.60%)	207 (3.81%)	5,215 (0.90%)
18 - 49 years	45,853 (24.12%)	42,172 (22.67%)	11,755 (13.55%)	8,445 (11.30%)	4,384 (11.59%)	618 (11.39%)	113,227 (19.49%)
50 - 64 years	50,602 (26.62%)	40,997 (22.04%)	13,723 (15.81%)	11,136 (14.90%)	5,112 (13.51%)	721 (13.28%)	122,291 (21.05%)
65 - 74 years	40,180 (21.14%)	39,031 (20.98%)	18,563 (21.39%)	16,150 (21.62%)	7,606 (20.11%)	1,127 (20.76%)	122,657 (21.12%)
75 - 84 years	33,311 (17.52%)	37,284 (20.04%)	23,858 (27.49%)	21,715 (29.06%)	10,674 (28.21%)	1,460 (26.90%)	128,302 (22.09%)
85+ years	18,331 (9.64%)	23,112 (12.42%)	17,447 (20.11%)	15,456 (20.69%)	7,342 (19.41%)	978 (18.02%)	82,666 (14.23%)
Sex							
Female	93,391 (49.13%)	95,702 (51.45%)	45,102 (51.98%)	38,247 (51.19%)	19,483 (51.50%)	2,796 (51.51%)	294,721 (50.74%)
Male	96,047 (50.53%)	89,644 (48.19%)	41,316 (47.61%)	36,097 (48.31%)	18,173 (48.04%)	2,565 (47.25%)	283,842 (48.87%)
Other	3 (0.00%)	2 (0.00%)	2 (0.00%)	1 (0.00%)	0	0	8 (0.00%)
Unknown	640 (0.34%)	675 (0.36%)	355 (0.41%)	371 (0.50%)	175 (0.46%)	67 (1.23%)	2,283 (0.39%)
Race							
White	123,591 (65.02%)	127,246 (68.40%)	61,334 (70.68%)	52,028 (69.63%)	25,373 (67.07%)	3,534 (65.11%)	393,106 (67.68%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Black or African American	28,696 (15.10%)	26,496 (14.24%)	10,688 (12.32%)	9,436 (12.63%)	5,015 (13.26%)	722 (13.30%)	81,053 (13.95%)
Asian	4,213 (2.22%)	3,581 (1.93%)	2,056 (2.37%)	1,951 (2.61%)	1,234 (3.26%)	229 (4.22%)	13,264 (2.28%)
Native Hawaiian or Other Pacific Islander	880 (0.46%)	757 (0.41%)	305 (0.35%)	288 (0.39%)	138 (0.36%)	11 (0.20%)	2,379 (0.41%)
American Indian or Alaska Native	1,077 (0.57%)	1,052 (0.57%)	429 (0.49%)	374 (0.50%)	195 (0.52%)	31 (0.57%)	3,158 (0.54%)
Other Race	11,718 (6.16%)	8,523 (4.58%)	3,698 (4.26%)	3,353 (4.49%)	2,325 (6.15%)	376 (6.93%)	29,993 (5.16%)
Unknown	19,906 (10.47%)	18,368 (9.87%)	8,265 (9.52%)	7,286 (9.75%)	3,551 (9.39%)	525 (9.67%)	57,901 (9.97%)
Ethnicity							
Hispanic or Latino	22,502 (11.84%)	15,394 (8.28%)	6,223 (7.17%)	5,943 (7.95%)	3,458 (9.14%)	464 (8.55%)	53,984 (9.29%)
Not Hispanic or Latino	147,505 (77.60%)	153,143 (82.32%)	72,711 (83.79%)	62,352 (83.45%)	31,514 (83.30%)	4,582 (84.41%)	471,807 (81.23%)
Unknown	20,074 (10.56%)	17,486 (9.40%)	7,841 (9.04%)	6,421 (8.59%)	2,859 (7.56%)	382 (7.04%)	55,063 (9.48%)
Comorbidity							
Asthma	15,387 (8.09%)	17,090 (9.19%)	8,729 (10.06%)	8,319 (11.13%)	4,741 (12.53%)	711 (13.10%)	54,977 (9.46%)
Chronic Lung Disease	11,543 (6.07%)	11,844 (6.37%)	6,329 (7.29%)	5,837 (7.81%)	3,064 (8.10%)	489 (9.01%)	39,106 (6.73%)
Chronic Obstructive Pulmonary Disease	20,674 (10.88%)	27,273 (14.66%)	15,597 (17.97%)	14,737 (19.72%)	7,231 (19.11%)	1,063 (19.58%)	86,575 (14.90%)

Hospitalization rate over time

The rate of COVID-associated hospitalization is shown in Figure 4. Figure 5 shows seasonal trends.

Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2020



Figure 5: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 37,730,816 COVID lab results with known results of which 4,126,713 were positive. The COVID test positivity rate is shown in Figure 6. Figure 7 shows yearly trends.

Figure 6: Weekly COVID test positivity rate since October 2020

Figure 7: Weekly COVID test positivity rate by season



Influenza

Our influenza study population consists of 179,809 hospitalizations of 144,603 unique patients (Table 3).

Table 3: Influenza patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	7,274 (100.00%)	13,697 (100.00%)	34,011 (100.00%)	36,988 (100.00%)	43,923 (100.00%)	8,710 (100.00%)	144,603 (100.00%)
Age Group							
< 6 months	293 (4.03%)	456 (3.33%)	783 (2.30%)	530 (1.43%)	120 (0.27%)	34 (0.39%)	2,216 (1.53%)
6 - <12 months	165 (2.27%)	311 (2.27%)	469 (1.38%)	325 (0.88%)	106 (0.24%)	25 (0.29%)	1,401 (0.97%)
1 - <2 years	320 (4.40%)	523 (3.82%)	715 (2.10%)	429 (1.16%)	171 (0.39%)	45 (0.52%)	2,203 (1.52%)
2 - 4 years	476 (6.54%)	990 (7.23%)	1,322 (3.89%)	737 (1.99%)	286 (0.65%)	81 (0.93%)	3,892 (2.69%)
5 - 17 years	564 (7.75%)	1,027 (7.50%)	1,998 (5.87%)	1,471 (3.98%)	890 (2.03%)	242 (2.78%)	6,192 (4.28%)
18 - 49 years	1,330 (18.28%)	2,495 (18.22%)	6,024 (17.71%)	7,191 (19.44%)	7,366 (16.77%)	1,444 (16.58%)	25,850 (17.88%)
50 - 64 years	1,442 (19.82%)	2,141 (15.63%)	6,391 (18.79%)	7,708 (20.84%)	9,270 (21.11%)	1,400 (16.07%)	28,352 (19.61%)
65 - 74 years	1,151 (15.82%)	2,206 (16.11%)	6,475 (19.04%)	7,595 (20.53%)	10,059 (22.90%)	1,841 (21.14%)	29,327 (20.28%)
75 - 84 years	959 (13.18%)	2,102 (15.35%)	6,105 (17.95%)	7,064 (19.10%)	9,927 (22.60%)	2,204 (25.30%)	28,361 (19.61%)
85+ years	574 (7.89%)	1,446 (10.56%)	3,729 (10.96%)	3,938 (10.65%)	5,728 (13.04%)	1,394 (16.00%)	16,809 (11.62%)
Sex							
Female	3,484 (47.90%)	7,243 (52.88%)	18,389 (54.07%)	20,227 (54.69%)	23,962 (54.55%)	4,868 (55.89%)	78,173 (54.06%)
Male	3,765 (51.76%)	6,410 (46.80%)	15,499 (45.57%)	16,630 (44.96%)	19,831 (45.15%)	3,784 (43.44%)	65,919 (45.59%)
Other	0	0	2 (0.01%)	0	0	0	2 (0.00%)
Unknown	25 (0.34%)	44 (0.32%)	121 (0.36%)	131 (0.35%)	130 (0.30%)	58 (0.67%)	509 (0.35%)
Race							
White	3,378 (46.44%)	7,196 (52.54%)	19,017 (55.91%)	21,286 (57.55%)	29,027 (66.09%)	5,410 (62.11%)	85,314 (59.00%)
Black or African American	1,414 (19.44%)	2,298 (16.78%)	6,157 (18.10%)	7,517 (20.32%)	6,669 (15.18%)	1,787 (20.52%)	25,842 (17.87%)
Asian	414 (5.69%)	765 (5.59%)	1,554 (4.57%)	1,159 (3.13%)	1,130 (2.57%)	271 (3.11%)	5,293 (3.66%)
Native Hawaiian or Other Pacific Islander	7 (0.10%)	63 (0.46%)	151 (0.44%)	193 (0.52%)	215 (0.49%)	73 (0.84%)	702 (0.49%)
American Indian or Alaska Native	46 (0.63%)	86 (0.63%)	235 (0.69%)	194 (0.52%)	265 (0.60%)	47 (0.54%)	873 (0.60%)
Other Race	1,300 (17.87%)	1,919 (14.01%)	3,397 (9.99%)	2,948 (7.97%)	2,862 (6.52%)	444 (5.10%)	12,870 (8.90%)
Unknown	715 (9.83%)	1,370 (10.00%)	3,500 (10.29%)	3,691 (9.98%)	3,755 (8.55%)	678 (7.78%)	13,709 (9.48%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Ethnicity							
Hispanic or Latino	891 (12.25%)	1,693 (12.36%)	3,824 (11.24%)	3,971 (10.74%)	5,028 (11.45%)	857 (9.84%)	16,264 (11.25%)
Not Hispanic or Latino	5,269 (72.44%)	10,498 (76.64%)	26,802 (78.80%)	29,630 (80.11%)	35,839 (81.60%)	7,300 (83.81%)	115,338 (79.76%)
Unknown	1,114 (15.31%)	1,506 (11.00%)	3,385 (9.95%)	3,387 (9.16%)	3,056 (6.96%)	553 (6.35%)	13,001 (8.99%)
Comorbidity							
Asthma	739 (10.16%)	1,877 (13.70%)	4,883 (14.36%)	5,422 (14.66%)	6,577 (14.97%)	1,395 (16.02%)	20,893 (14.45%)
Chronic Lung Disease	224 (3.08%)	768 (5.61%)	2,286 (6.72%)	2,740 (7.41%)	4,092 (9.32%)	783 (8.99%)	10,893 (7.53%)
Chronic Obstructive Pulmonary Disease	702 (9.65%)	2,037 (14.87%)	5,873 (17.27%)	6,923 (18.72%)	9,513 (21.66%)	1,770 (20.32%)	26,818 (18.55%)

Hospitalization rate over time

The rate of influenza-associated hospitalization is shown in Figure 8. Figure 9 shows seasonal trends.

Figure 8: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2020

Figure 9: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 21,302,022 influenza lab results with known results of which 2,008,412 were positive. The influenza test positivity rate is shown in Figure 10. Figure 11 shows yearly trends.

Figure 10: Weekly influenza test positivity rate since October 2020



Figure 11: Weekly influenza test positivity rate by season



Human metapneumovirus (HMPV)

Our HMPV study population consists of 24,504 hospitalizations of 18,295 unique patients (Table 4).

Table 4: HMPV patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	98 (100.00%)	2,939 (100.00%)	4,913 (100.00%)	4,294 (100.00%)	5,439 (100.00%)	612 (100.00%)	18,295 (100.00%)
Age Group							
< 6 months	1 (1.02%)	81 (2.76%)	186 (3.79%)	97 (2.26%)	111 (2.04%)	12 (1.96%)	488 (2.67%)
6 - <12 months	5 (5.10%)	120 (4.08%)	154 (3.13%)	124 (2.89%)	120 (2.21%)	14 (2.29%)	537 (2.94%)
1 - <2 years	10 (10.20%)	173 (5.89%)	202 (4.11%)	114 (2.65%)	144 (2.65%)	25 (4.08%)	668 (3.65%)
2 - 4 years	11 (11.22%)	262 (8.91%)	339 (6.90%)	176 (4.10%)	186 (3.42%)	18 (2.94%)	992 (5.42%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
5 - 17 years	2 (2.04%)	131 (4.46%)	191 (3.89%)	135 (3.14%)	141 (2.59%)	21 (3.43%)	621 (3.39%)
18 - 49 years	16 (16.33%)	362 (12.32%)	537 (10.93%)	537 (12.51%)	673 (12.37%)	83 (13.56%)	2,208 (12.07%)
50 - 64 years	23 (23.47%)	530 (18.03%)	846 (17.22%)	783 (18.23%)	932 (17.14%)	101 (16.50%)	3,215 (17.57%)
65 - 74 years	8 (8.16%)	516 (17.56%)	919 (18.71%)	841 (19.59%)	1,090 (20.04%)	130 (21.24%)	3,504 (19.15%)
75 - 84 years	14 (14.29%)	490 (16.67%)	946 (19.26%)	932 (21.70%)	1,239 (22.78%)	121 (19.77%)	3,742 (20.45%)
85+ years	8 (8.16%)	274 (9.32%)	593 (12.07%)	555 (12.93%)	803 (14.76%)	87 (14.22%)	2,320 (12.68%)
Sex							
Female	48 (48.98%)	1,654 (56.28%)	2,862 (58.25%)	2,616 (60.92%)	3,192 (58.69%)	361 (58.99%)	10,733 (58.67%)
Male	49 (50.00%)	1,277 (43.45%)	2,041 (41.54%)	1,663 (38.73%)	2,231 (41.02%)	246 (40.20%)	7,507 (41.03%)
Unknown	1 (1.02%)	8 (0.27%)	10 (0.20%)	15 (0.35%)	16 (0.29%)	5 (0.82%)	55 (0.30%)
Race							
White	69 (70.41%)	2,150 (73.15%)	3,490 (71.04%)	2,902 (67.58%)	3,716 (68.32%)	413 (67.48%)	12,740 (69.64%)
Black or African American	7 (7.14%)	324 (11.02%)	514 (10.46%)	514 (11.97%)	699 (12.85%)	79 (12.91%)	2,137 (11.68%)
Asian	0	59 (2.01%)	133 (2.71%)	98 (2.28%)	141 (2.59%)	19 (3.10%)	450 (2.46%)
Native Hawaiian or Other Pacific Islander	0	18 (0.61%)	16 (0.33%)	18 (0.42%)	20 (0.37%)	5 (0.82%)	77 (0.42%)
American Indian or Alaska Native	2 (2.04%)	21 (0.71%)	43 (0.88%)	25 (0.58%)	24 (0.44%)	4 (0.65%)	119 (0.65%)
Other Race	10 (10.20%)	162 (5.51%)	336 (6.84%)	317 (7.38%)	360 (6.62%)	37 (6.05%)	1,222 (6.68%)
Unknown	10 (10.20%)	205 (6.98%)	381 (7.75%)	420 (9.78%)	479 (8.81%)	55 (8.99%)	1,550 (8.47%)
Ethnicity							
Hispanic or Latino	22 (22.45%)	353 (12.01%)	677 (13.78%)	655 (15.25%)	764 (14.05%)	94 (15.36%)	2,565 (14.02%)
Not Hispanic or Latino	68 (69.39%)	2,376 (80.84%)	3,920 (79.79%)	3,340 (77.78%)	4,304 (79.13%)	485 (79.25%)	14,493 (79.22%)
Unknown	8 (8.16%)	210 (7.15%)	316 (6.43%)	299 (6.96%)	371 (6.82%)	33 (5.39%)	1,237 (6.76%)
Comorbidity							
Asthma	13 (13.27%)	425 (14.46%)	767 (15.61%)	730 (17.00%)	904 (16.62%)	101 (16.50%)	2,940 (16.07%)
Chronic Lung Disease	11 (11.22%)	307 (10.45%)	477 (9.71%)	423 (9.85%)	609 (11.20%)	55 (8.99%)	1,882 (10.29%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Chronic Obstructive Pulmonary Disease	18 (18.37%)	600 (20.42%)	991 (20.17%)	852 (19.84%)	1,173 (21.57%)	97 (15.85%)	3,731 (20.39%)

Hospitalization rate over time

The rate of HMPV-associated hospitalization is shown in Figure 12. Figure 13 shows seasonal trends.

Figure 12: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2020



Figure 13: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 2,582,540 HMPV lab results with known results of which 65,552 were positive. The HMPV test positivity rate is shown in Figure 14. Figure 15 shows yearly trends.

Figure 14: Weekly HMPV test positivity rate since October 2020



Figure 15: Weekly HMPV test positivity rate by season



Parainfluenza virus

Our parainfluenza study population consists of 27,559 hospitalizations of 20,098 unique patients (Table 5).

Table 5: Parainfluenza patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	1,499 (100.00%)	2,411 (100.00%)	4,575 (100.00%)	4,909 (100.00%)	5,412 (100.00%)	1,292 (100.00%)	20,098 (100.00%)
Age Group							
< 6 months	96 (6.40%)	119 (4.94%)	221 (4.83%)	165 (3.36%)	155 (2.86%)	40 (3.10%)	796 (3.96%)
6 - <12 months	72 (4.80%)	85 (3.53%)	136 (2.97%)	105 (2.14%)	94 (1.74%)	35 (2.71%)	527 (2.62%)
1 - <2 years	103 (6.87%)	105 (4.36%)	191 (4.17%)	151 (3.08%)	155 (2.86%)	64 (4.95%)	769 (3.83%)
2 - 4 years	92 (6.14%)	145 (6.01%)	238 (5.20%)	180 (3.67%)	171 (3.16%)	60 (4.64%)	886 (4.41%)
5 - 17 years	71 (4.74%)	111 (4.60%)	202 (4.42%)	142 (2.89%)	161 (2.97%)	65 (5.03%)	752 (3.74%)
18 - 49 years	225 (15.01%)	315 (13.07%)	565 (12.35%)	595 (12.12%)	682 (12.60%)	161 (12.46%)	2,543 (12.65%)
50 - 64 years	303 (20.21%)	494 (20.49%)	825 (18.03%)	904 (18.42%)	949 (17.54%)	219 (16.95%)	3,694 (18.38%)
65 - 74 years	237 (15.81%)	448 (18.58%)	838 (18.32%)	1,042 (21.23%)	1,129 (20.86%)	257 (19.89%)	3,951 (19.66%)
75 - 84 years	192 (12.81%)	348 (14.43%)	825 (18.03%)	1,033 (21.04%)	1,187 (21.93%)	240 (18.58%)	3,825 (19.03%)
85+ years	108 (7.20%)	241 (10.00%)	534 (11.67%)	592 (12.06%)	729 (13.47%)	151 (11.69%)	2,355 (11.72%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Sex							
Female	797 (53.17%)	1,367 (56.70%)	2,476 (54.12%)	2,669 (54.37%)	2,974 (54.95%)	684 (52.94%)	10,967 (54.57%)
Male	699 (46.63%)	1,041 (43.18%)	2,085 (45.57%)	2,228 (45.39%)	2,419 (44.70%)	597 (46.21%)	9,069 (45.12%)
Unknown	3 (0.20%)	3 (0.12%)	14 (0.31%)	12 (0.24%)	19 (0.35%)	11 (0.85%)	62 (0.31%)
Race							
White	1,028 (68.58%)	1,701 (70.55%)	3,136 (68.55%)	3,271 (66.63%)	3,646 (67.37%)	889 (68.81%)	13,671 (68.02%)
Black or African American	203 (13.54%)	291 (12.07%)	572 (12.50%)	623 (12.69%)	689 (12.73%)	166 (12.85%)	2,544 (12.66%)
Asian	18 (1.20%)	49 (2.03%)	114 (2.49%)	114 (2.32%)	126 (2.33%)	23 (1.78%)	444 (2.21%)
Native Hawaiian or Other Pacific Islander	6 (0.40%)	11 (0.46%)	24 (0.52%)	38 (0.77%)	21 (0.39%)	8 (0.62%)	108 (0.54%)
American Indian or Alaska Native	15 (1.00%)	19 (0.79%)	38 (0.83%)	32 (0.65%)	32 (0.59%)	7 (0.54%)	143 (0.71%)
Other Race	92 (6.14%)	126 (5.23%)	316 (6.91%)	328 (6.68%)	385 (7.11%)	89 (6.89%)	1,336 (6.65%)
Unknown	137 (9.14%)	214 (8.88%)	375 (8.20%)	503 (10.25%)	513 (9.48%)	110 (8.51%)	1,852 (9.21%)
Ethnicity							
Hispanic or Latino	147 (9.81%)	282 (11.70%)	607 (13.27%)	691 (14.08%)	713 (13.17%)	195 (15.09%)	2,635 (13.11%)
Not Hispanic or Latino	1,234 (82.32%)	1,932 (80.13%)	3,603 (78.75%)	3,858 (78.59%)	4,364 (80.64%)	1,032 (79.88%)	16,023 (79.72%)
Unknown	118 (7.87%)	197 (8.17%)	365 (7.98%)	360 (7.33%)	335 (6.19%)	65 (5.03%)	1,440 (7.16%)
Comorbidity							
Asthma	250 (16.68%)	403 (16.72%)	733 (16.02%)	800 (16.30%)	914 (16.89%)	219 (16.95%)	3,319 (16.51%)
Chronic Lung Disease	158 (10.54%)	286 (11.86%)	498 (10.89%)	530 (10.80%)	640 (11.83%)	131 (10.14%)	2,243 (11.16%)
Chronic Obstructive Pulmonary Disease	341 (22.75%)	583 (24.18%)	1,068 (23.34%)	1,236 (25.18%)	1,338 (24.72%)	277 (21.44%)	4,843 (24.10%)

Hospitalization rate over time

The rate of parainfluenza-associated hospitalization is shown in Figure 16. Figure 17 shows seasonal trends.

Figure 16: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions since October 2020

Figure 17: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 2,683,422 parainfluenza lab results with known results of which 104,407 were positive. The parainfluenza test positivity rate is shown in Figure 18. Figure 19 shows yearly trends.

Figure 18: Weekly parainfluenza test positivity rate since October 2020

Figure 19: Weekly parainfluenza test positivity rate by season



Respiratory syncytial virus (RSV)

Our RSV study population consists of 59,303 hospitalizations of 42,426 unique patients (Table 6).

Table 6: RSV patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	2,336 (100.00%)	4,937 (100.00%)	9,363 (100.00%)	11,538 (100.00%)	12,252 (100.00%)	2,000 (100.00%)	42,426 (100.00%)
Age Group							
< 6 months	603 (25.81%)	907 (18.37%)	1,693 (18.08%)	1,264 (10.96%)	914 (7.46%)	192 (9.60%)	5,573 (13.14%)
6 - <12 months	210 (8.99%)	380 (7.70%)	662 (7.07%)	584 (5.06%)	553 (4.51%)	103 (5.15%)	2,492 (5.87%)
1 - <2 years	234 (10.02%)	418 (8.47%)	729 (7.79%)	609 (5.28%)	645 (5.26%)	189 (9.45%)	2,824 (6.66%)
2 - 4 years	191 (8.18%)	426 (8.63%)	815 (8.70%)	513 (4.45%)	673 (5.49%)	157 (7.85%)	2,775 (6.54%)
5 - 17 years	45 (1.93%)	128 (2.59%)	285 (3.04%)	249 (2.16%)	277 (2.26%)	63 (3.15%)	1,047 (2.47%)
18 - 49 years	231 (9.89%)	438 (8.87%)	794 (8.48%)	1,035 (8.97%)	1,225 (10.00%)	191 (9.55%)	3,914 (9.23%)
50 - 64 years	275 (11.77%)	594 (12.03%)	1,047 (11.18%)	1,693 (14.67%)	1,853 (15.12%)	265 (13.25%)	5,727 (13.50%)
65 - 74 years	249 (10.66%)	615 (12.46%)	1,217 (13.00%)	1,935 (16.77%)	2,100 (17.14%)	276 (13.80%)	6,392 (15.07%)
75 - 84 years	187 (8.01%)	644 (13.04%)	1,258 (13.44%)	2,129 (18.45%)	2,387 (19.48%)	325 (16.25%)	6,930 (16.33%)
85+ years	111 (4.75%)	387 (7.84%)	863 (9.22%)	1,527 (13.23%)	1,625 (13.26%)	239 (11.95%)	4,752 (11.20%)
Sex							
Female	1,284 (54.97%)	2,538 (51.41%)	4,980 (53.19%)	6,340 (54.95%)	6,696 (54.65%)	1,120 (56.00%)	22,958 (54.11%)
Male	1,047 (44.82%)	2,389 (48.39%)	4,357 (46.53%)	5,157 (44.70%)	5,516 (45.02%)	869 (43.45%)	19,335 (45.57%)
Unknown	5 (0.21%)	10 (0.20%)	26 (0.28%)	41 (0.36%)	40 (0.33%)	11 (0.55%)	133 (0.31%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Race							
White	1,499 (64.17%)	3,368 (68.22%)	6,165 (65.84%)	7,841 (67.96%)	7,869 (64.23%)	1,178 (58.90%)	27,920 (65.81%)
Black or African American	427 (18.28%)	604 (12.23%)	1,128 (12.05%)	1,448 (12.55%)	1,676 (13.68%)	367 (18.35%)	5,650 (13.32%)
Asian	38 (1.63%)	144 (2.92%)	324 (3.46%)	312 (2.70%)	362 (2.95%)	68 (3.40%)	1,248 (2.94%)
Native Hawaiian or Other Pacific Islander	17 (0.73%)	86 (1.74%)	171 (1.83%)	121 (1.05%)	185 (1.51%)	27 (1.35%)	607 (1.43%)
American Indian or Alaska Native	15 (0.64%)	48 (0.97%)	78 (0.83%)	68 (0.59%)	71 (0.58%)	13 (0.65%)	293 (0.69%)
Other Race	162 (6.93%)	261 (5.29%)	586 (6.26%)	571 (4.95%)	901 (7.35%)	169 (8.45%)	2,650 (6.25%)
Unknown	178 (7.62%)	426 (8.63%)	911 (9.73%)	1,177 (10.20%)	1,188 (9.70%)	178 (8.90%)	4,058 (9.56%)
Ethnicity							
Hispanic or Latino	339 (14.51%)	668 (13.53%)	1,383 (14.77%)	1,397 (12.11%)	1,784 (14.56%)	358 (17.90%)	5,929 (13.97%)
Not Hispanic or Latino	1,820 (77.91%)	3,872 (78.43%)	7,243 (77.36%)	9,230 (80.00%)	9,574 (78.14%)	1,519 (75.95%)	33,258 (78.39%)
Unknown	177 (7.58%)	397 (8.04%)	737 (7.87%)	911 (7.90%)	894 (7.30%)	123 (6.15%)	3,239 (7.63%)
Comorbidity							
Asthma	278 (11.90%)	601 (12.17%)	1,207 (12.89%)	1,653 (14.33%)	1,946 (15.88%)	318 (15.90%)	6,003 (14.15%)
Chronic Lung Disease	143 (6.12%)	338 (6.85%)	626 (6.69%)	917 (7.95%)	1,124 (9.17%)	159 (7.95%)	3,307 (7.79%)
Chronic Obstructive Pulmonary Disease	313 (13.40%)	795 (16.10%)	1,506 (16.08%)	2,357 (20.43%)	2,525 (20.61%)	326 (16.30%)	7,822 (18.44%)

Hospitalization rate over time

The rate of RSV-associated hospitalization is shown in Figure 20. Figure 21 shows seasonal trends.

Figure 20: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2020



Figure 21: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 8,772,493 RSV lab results with known results of which 400,289 were positive. The RSV test positivity rate is shown in Figure 22. Figure 23 shows yearly trends.

Figure 22: Weekly RSV test positivity rate since October 2020



Figure 23: Weekly RSV test positivity rate by season



Rhinovirus

Our rhinovirus study population consists of 114,183 hospitalizations of 79,091 unique patients (Table 7).

Table 7: Rhinovirus patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	6,842 (100.00%)	9,477 (100.00%)	15,381 (100.00%)	17,329 (100.00%)	22,453 (100.00%)	7,609 (100.00%)	79,091 (100.00%)
Age Group							
< 6 months	470 (6.87%)	786 (8.29%)	919 (5.97%)	891 (5.14%)	919 (4.09%)	243 (3.19%)	4,228 (5.35%)
6 - <12 months	289 (4.22%)	377 (3.98%)	469 (3.05%)	457 (2.64%)	484 (2.16%)	129 (1.70%)	2,205 (2.79%)
1 - <2 years	548 (8.01%)	729 (7.69%)	837 (5.44%)	804 (4.64%)	918 (4.09%)	277 (3.64%)	4,113 (5.20%)
2 - 4 years	512 (7.48%)	1,068 (11.27%)	1,257 (8.17%)	1,113 (6.42%)	1,253 (5.58%)	374 (4.92%)	5,577 (7.05%)
5 - 17 years	623 (9.11%)	1,039 (10.96%)	1,454 (9.45%)	1,614 (9.31%)	1,844 (8.21%)	509 (6.69%)	7,083 (8.96%)
18 - 49 years	1,486 (21.72%)	1,516 (16.00%)	2,666 (17.33%)	3,257 (18.80%)	4,413 (19.65%)	1,451 (19.07%)	14,789 (18.70%)
50 - 64 years	1,115 (16.30%)	1,335 (14.09%)	2,476 (16.10%)	2,771 (15.99%)	3,788 (16.87%)	1,345 (17.68%)	12,830 (16.22%)
65 - 74 years	838 (12.25%)	1,210 (12.77%)	2,344 (15.24%)	2,719 (15.69%)	3,691 (16.44%)	1,334 (17.53%)	12,136 (15.34%)
75 - 84 years	616 (9.00%)	886 (9.35%)	1,893 (12.31%)	2,278 (13.15%)	3,269 (14.56%)	1,222 (16.06%)	10,164 (12.85%)
85+ years	345 (5.04%)	531 (5.60%)	1,066 (6.93%)	1,425 (8.22%)	1,874 (8.35%)	725 (9.53%)	5,966 (7.54%)
Sex							
Female	3,486 (50.95%)	4,637 (48.93%)	7,696 (50.04%)	8,698 (50.19%)	11,194 (49.86%)	3,836 (50.41%)	39,547 (50.00%)
Male	3,340 (48.82%)	4,814 (50.80%)	7,635 (49.64%)	8,581 (49.52%)	11,179 (49.79%)	3,720 (48.89%)	39,269 (49.65%)
Other	0	0	0	0	1 (0.00%)	0	1 (0.00%)
Unknown	16 (0.23%)	26 (0.27%)	50 (0.33%)	50 (0.29%)	79 (0.35%)	53 (0.70%)	274 (0.35%)
Race							
White	4,418 (64.57%)	6,199 (65.41%)	9,845 (64.01%)	10,826 (62.47%)	14,103 (62.81%)	4,897 (64.36%)	50,288 (63.58%)
Black or African American	1,104 (16.14%)	1,460 (15.41%)	2,424 (15.76%)	2,712 (15.65%)	3,704 (16.50%)	1,246 (16.38%)	12,650 (15.99%)
Asian	153 (2.24%)	201 (2.12%)	355 (2.31%)	336 (1.94%)	434 (1.93%)	142 (1.87%)	1,621 (2.05%)
Native Hawaiian or Other Pacific Islander	63 (0.92%)	75 (0.79%)	83 (0.54%)	97 (0.56%)	133 (0.59%)	37 (0.49%)	488 (0.62%)
American Indian or Alaska Native	47 (0.69%)	83 (0.88%)	119 (0.77%)	101 (0.58%)	127 (0.57%)	40 (0.53%)	517 (0.65%)
Other Race	466 (6.81%)	678 (7.15%)	1,131 (7.35%)	1,544 (8.91%)	1,900 (8.46%)	575 (7.56%)	6,294 (7.96%)
Unknown	591 (8.64%)	781 (8.24%)	1,424 (9.26%)	1,713 (9.89%)	2,052 (9.14%)	672 (8.83%)	7,233 (9.15%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Ethnicity							
Hispanic or Latino	793 (11.59%)	1,304 (13.76%)	2,335 (15.18%)	2,912 (16.80%)	3,659 (16.30%)	1,216 (15.98%)	12,219 (15.45%)
Not Hispanic or Latino	5,539 (80.96%)	7,467 (78.79%)	11,926 (77.54%)	13,193 (76.13%)	17,326 (77.17%)	6,010 (78.99%)	61,461 (77.71%)
Unknown	510 (7.45%)	706 (7.45%)	1,120 (7.28%)	1,224 (7.06%)	1,468 (6.54%)	383 (5.03%)	5,411 (6.84%)
Comorbidity							
Asthma	1,335 (19.51%)	1,663 (17.55%)	2,764 (17.97%)	3,190 (18.41%)	4,210 (18.75%)	1,435 (18.86%)	14,597 (18.46%)
Chronic Lung Disease	690 (10.08%)	809 (8.54%)	1,323 (8.60%)	1,439 (8.30%)	2,155 (9.60%)	702 (9.23%)	7,118 (9.00%)
Chronic Obstructive Pulmonary Disease	1,275 (18.63%)	1,561 (16.47%)	2,720 (17.68%)	2,980 (17.20%)	4,210 (18.75%)	1,582 (20.79%)	14,328 (18.12%)

Hospitalization rate over time

The rate of rhinovirus-associated hospitalization is shown in Figure 24. Figure 25 shows seasonal trends.

Figure 24: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2020

Figure 25: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 2,601,828 rhinovirus lab results with known results of which 427,768 were positive. The rhinovirus test positivity rate is shown in Figure 26. Figure 27 shows yearly trends.

Figure 26: Weekly rhinovirus test positivity rate since October 2020

Figure 27: Weekly rhinovirus test positivity rate by season



Infants and children (age 0-4)

Our infants and children study population consists of 76,618 hospitalizations of 51,658 unique patients (Table 8).

Table 8: Infants and children patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	5,342 (100.00%)	10,206 (100.00%)	13,206 (100.00%)	10,563 (100.00%)	9,907 (100.00%)	2,434 (100.00%)	51,658 (100.00%)
Age Group							
< 6 months	1,805 (33.79%)	3,207 (31.42%)	4,225 (31.99%)	3,388 (32.07%)	2,622 (26.47%)	586 (24.08%)	15,833 (30.65%)
6 - <12 months	803 (15.03%)	1,545 (15.14%)	2,076 (15.72%)	1,814 (17.17%)	1,601 (16.16%)	338 (13.89%)	8,177 (15.83%)
1 - <2 years	1,311 (24.54%)	2,200 (21.56%)	2,810 (21.28%)	2,376 (22.49%)	2,495 (25.18%)	684 (28.10%)	11,876 (22.99%)
2 - 4 years	1,423 (26.64%)	3,254 (31.88%)	4,095 (31.01%)	2,985 (28.26%)	3,189 (32.19%)	826 (33.94%)	15,772 (30.53%)
Sex							

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Female	2,274 (42.57%)	4,266 (41.80%)	5,701 (43.17%)	4,568 (43.25%)	4,307 (43.47%)	1,028 (42.24%)	22,144 (42.87%)
Male	3,068 (57.43%)	5,938 (58.18%)	7,504 (56.82%)	5,992 (56.73%)	5,598 (56.51%)	1,406 (57.76%)	29,506 (57.12%)
Unknown	0	2 (0.02%)	1 (0.01%)	3 (0.03%)	2 (0.02%)	0	8 (0.02%)
Race							
White	2,745 (51.39%)	5,302 (51.95%)	6,510 (49.30%)	5,177 (49.01%)	4,840 (48.85%)	1,255 (51.56%)	25,829 (50.00%)
Black or African American	980 (18.35%)	1,636 (16.03%)	2,077 (15.73%)	1,676 (15.87%)	1,616 (16.31%)	426 (17.50%)	8,411 (16.28%)
Asian	230 (4.31%)	582 (5.70%)	910 (6.89%)	566 (5.36%)	468 (4.72%)	110 (4.52%)	2,866 (5.55%)
Native Hawaiian or Other Pacific Islander	88 (1.65%)	202 (1.98%)	256 (1.94%)	241 (2.28%)	263 (2.65%)	54 (2.22%)	1,104 (2.14%)
American Indian or Alaska Native	43 (0.80%)	112 (1.10%)	166 (1.26%)	82 (0.78%)	73 (0.74%)	19 (0.78%)	495 (0.96%)
Other Race	912 (17.07%)	1,526 (14.95%)	2,012 (15.24%)	1,607 (15.21%)	1,632 (16.47%)	356 (14.63%)	8,045 (15.57%)
Unknown	344 (6.44%)	846 (8.29%)	1,275 (9.65%)	1,214 (11.49%)	1,015 (10.25%)	214 (8.79%)	4,908 (9.50%)
Ethnicity							
Hispanic or Latino	1,118 (20.93%)	2,173 (21.29%)	3,235 (24.50%)	2,709 (25.65%)	2,739 (27.65%)	659 (27.07%)	12,633 (24.46%)
Not Hispanic or Latino	3,846 (72.00%)	7,280 (71.33%)	9,027 (68.36%)	7,187 (68.04%)	6,507 (65.68%)	1,642 (67.46%)	35,489 (68.70%)
Unknown	378 (7.08%)	753 (7.38%)	944 (7.15%)	667 (6.31%)	661 (6.67%)	133 (5.46%)	3,536 (6.85%)
Virus							
COVID	641 (12.00%)	1,745 (17.10%)	869 (6.58%)	1,195 (11.31%)	1,729 (17.45%)	317 (13.02%)	6,496 (12.58%)
HMPV	27 (0.51%)	636 (6.23%)	881 (6.67%)	511 (4.84%)	561 (5.66%)	69 (2.83%)	2,685 (5.20%)
RSV	1,238 (23.17%)	2,131 (20.88%)	3,899 (29.52%)	2,970 (28.12%)	2,785 (28.11%)	641 (26.34%)	13,664 (26.45%)
influenza	1,254 (23.47%)	2,280 (22.34%)	3,289 (24.91%)	2,021 (19.13%)	683 (6.89%)	185 (7.60%)	9,712 (18.80%)
parainfluenza	363 (6.80%)	454 (4.45%)	786 (5.95%)	601 (5.69%)	575 (5.80%)	199 (8.18%)	2,978 (5.76%)
rhinovirus	1,819 (34.05%)	2,960 (29.00%)	3,482 (26.37%)	3,265 (30.91%)	3,574 (36.08%)	1,023 (42.03%)	16,123 (31.21%)
Comorbidity							
Asthma	410 (7.68%)	682 (6.68%)	918 (6.95%)	832 (7.88%)	964 (9.73%)	266 (10.93%)	4,072 (7.88%)
Chronic Lung Disease	35 (0.66%)	60 (0.59%)	87 (0.66%)	75 (0.71%)	72 (0.73%)	24 (0.99%)	353 (0.68%)
Chronic Obstructive Pulmonary Disease	8 (0.15%)	17 (0.17%)	19 (0.14%)	20 (0.19%)	14 (0.14%)	6 (0.25%)	84 (0.16%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 28. Figure 29 shows the same data stacked to represent the combined impact of the viruses.

Figure 28: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five



Figure 29: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five



Test positivity rate over time

We included 8,355,442 lab results with known results of infants and children under age five. Of those tests, 1,001,050 lab results were positive. The test positivity rate for infants and children under age five is shown in Figure 30.

Figure 30: Weekly test positivity rate since October 2020 for infants and children under five



Older adults (age 65 and over)

Our older adults study population consists of 531,022 hospitalizations of 474,159 unique patients (Table 9).

Table 9: Older adults patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
N	97,419 (100.00%)	111,771 (100.00%)	89,473 (100.00%)	88,926 (100.00%)	72,459 (100.00%)	14,111 (100.00%)	474,159 (100.00%)
Age Group							
65 - 74 years	42,663 (43.79%)	44,026 (39.39%)	30,356 (33.93%)	30,282 (34.05%)	25,675 (35.43%)	4,965 (35.19%)	177,967 (37.53%)
75 - 84 years	35,279 (36.21%)	41,754 (37.36%)	34,885 (38.99%)	35,151 (39.53%)	28,683 (39.59%)	5,572 (39.49%)	181,324 (38.24%)
85+ years	19,477 (19.99%)	25,991 (23.25%)	24,232 (27.08%)	23,493 (26.42%)	18,101 (24.98%)	3,574 (25.33%)	114,868 (24.23%)
Sex							
Female	48,001 (49.27%)	56,422 (50.48%)	47,322 (52.89%)	46,927 (52.77%)	39,053 (53.90%)	7,629 (54.06%)	245,354 (51.75%)
Male	49,022 (50.32%)	54,891 (49.11%)	41,765 (46.68%)	41,554 (46.73%)	33,092 (45.67%)	6,332 (44.87%)	226,656 (47.80%)
Unknown	396 (0.41%)	458 (0.41%)	386 (0.43%)	445 (0.50%)	314 (0.43%)	150 (1.06%)	2,149 (0.45%)
Race							
White	71,292 (73.18%)	84,569 (75.66%)	67,130 (75.03%)	65,328 (73.46%)	53,822 (74.28%)	10,227 (72.48%)	352,368 (74.31%)
Black or African American	10,655 (10.94%)	11,391 (10.19%)	8,752 (9.78%)	9,564 (10.76%)	7,303 (10.08%)	1,697 (12.03%)	49,362 (10.41%)
Asian	1,718 (1.76%)	1,869 (1.67%)	1,978 (2.21%)	2,065 (2.32%)	1,797 (2.48%)	390 (2.76%)	9,817 (2.07%)
Native Hawaiian or Other Pacific Islander	156 (0.16%)	190 (0.17%)	164 (0.18%)	159 (0.18%)	152 (0.21%)	46 (0.33%)	867 (0.18%)
American Indian or Alaska Native	260 (0.27%)	334 (0.30%)	318 (0.36%)	296 (0.33%)	267 (0.37%)	51 (0.36%)	1,526 (0.32%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026	Overall
Other Race	3,226 (3.31%)	2,985 (2.67%)	2,938 (3.28%)	3,276 (3.68%)	3,041 (4.20%)	569 (4.03%)	16,035 (3.38%)
Unknown	10,112 (10.38%)	10,433 (9.33%)	8,193 (9.16%)	8,238 (9.26%)	6,077 (8.39%)	1,131 (8.02%)	44,184 (9.32%)
Ethnicity							
Hispanic or Latino	5,032 (5.17%)	4,445 (3.98%)	4,285 (4.79%)	5,074 (5.71%)	4,865 (6.71%)	931 (6.60%)	24,632 (5.19%)
Not Hispanic or Latino	80,929 (83.07%)	96,294 (86.15%)	76,874 (85.92%)	75,938 (85.39%)	62,300 (85.98%)	12,326 (87.35%)	404,661 (85.34%)
Unknown	11,458 (11.76%)	11,032 (9.87%)	8,314 (9.29%)	7,914 (8.90%)	5,294 (7.31%)	854 (6.05%)	44,866 (9.46%)
Virus							
COVID	91,822 (94.25%)	99,427 (88.96%)	59,868 (66.91%)	53,321 (59.96%)	25,622 (35.36%)	3,565 (25.26%)	333,625 (70.36%)
HMPV	30 (0.03%)	1,280 (1.15%)	2,458 (2.75%)	2,328 (2.62%)	3,132 (4.32%)	338 (2.40%)	9,566 (2.02%)
RSV	547 (0.56%)	1,646 (1.47%)	3,338 (3.73%)	5,591 (6.29%)	6,112 (8.44%)	840 (5.95%)	18,074 (3.81%)
influenza	2,684 (2.76%)	5,754 (5.15%)	16,309 (18.23%)	18,597 (20.91%)	25,714 (35.49%)	5,439 (38.54%)	74,497 (15.71%)
parainfluenza	537 (0.55%)	1,037 (0.93%)	2,197 (2.46%)	2,667 (3.00%)	3,045 (4.20%)	648 (4.59%)	10,131 (2.14%)
rhinovirus	1,799 (1.85%)	2,627 (2.35%)	5,303 (5.93%)	6,422 (7.22%)	8,834 (12.19%)	3,281 (23.25%)	28,266 (5.96%)
Comorbidity							
Asthma	7,601 (7.80%)	9,845 (8.81%)	9,374 (10.48%)	10,044 (11.29%)	9,280 (12.81%)	1,908 (13.52%)	48,052 (10.13%)
Chronic Lung Disease	7,080 (7.27%)	8,611 (7.70%)	7,795 (8.71%)	8,011 (9.01%)	7,862 (10.85%)	1,532 (10.86%)	40,891 (8.62%)
Chronic Obstructive Pulmonary Disease	17,041 (17.49%)	23,983 (21.46%)	20,990 (23.46%)	22,271 (25.04%)	19,587 (27.03%)	3,848 (27.27%)	107,720 (22.72%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in `Figure 31. Figure 32 shows the same data stacked to represent the combined impact of the viruses.

Figure 31: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older



Figure 32: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older



Test positivity rate over time

We included 21,572,402 lab results with known results of adults aged 65 and over. Of those tests, 1,508,805 lab results were positive. The test positivity rate for adults aged 65 and over is shown in Figure 33.

Figure 33: Weekly test positivity rate since October 2020 for adults 65 years or older



Discussion and conclusion

At the end of December 2025, respiratory virus-associated hospitalizations accounted for 6.9% of all hospitalizations, more than double the proportion at the beginning of

December (3.0%, +125.3%). Influenza-associated hospitalizations increased from 1.1% to 4.2% of all hospitalizations (+277.1%), COVID-associated hospitalizations increased from 0.6% to 1.0% of all hospitalizations (+61.8%), RSV-associated hospitalizations increased from 0.4% to 0.7% of all hospitalizations (+83.7%), and rhinovirus-associated hospitalizations decreased slightly from 1.0% to 0.8% of all hospitalizations (-19.3%). HMPV-, parainfluenza-associated hospitalizations all remained relatively low and stable across the month.

Influenza, COVID, and HMPV test positivity increased notably (+92.9%, +37.4%, and +108.7%, respectively), while RSV test positivity increased slightly (+22.5%). Rhinovirus and parainfluenza test positivity decreased (-32.9% and -34.3%, respectively).

The increases in respiratory virus-associated hospitalizations and test positivity indicate a clear seasonal escalation. Influenza was the primary driver, accounting for the largest rise in associated hospitalizations.

In the population aged 0–4 years, respiratory virus-associated hospitalizations remained stable throughout December and are now at a rate of 3.6% of all hospitalizations in this age group (-7.2%). This stability reflects opposing trends, with influenza-associated hospitalizations increasing from 0.8% to 1.2% of all hospitalizations (+44.6%), offset by declines in rhinovirus-, COVID-, and parainfluenza-associated hospitalizations (−54.0%, −29.5%, and -75.4% respectively). RSV-associated hospitalizations were stable overall, despite a brief increase observed in mid-December, and accounted for 1.7% of all hospitalizations by the end of the month, representing the largest share of respiratory virus-associated hospitalizations in this age group. HMPV-associated hospitalizations remained low and unchanged across the month (0.2%).

In this pediatric population, influenza, HMPV, and COVID test positivity increased substantially (+97.2%, +66.6%, +31.4%, respectively), while RSV test positivity increased slightly (+17.1%). Rhinovirus and parainfluenza test positivity decreased (-30.9% and -43.0%, respectively). Together, these patterns indicate a shift in the respiratory virus landscape among children aged 0 to 4 years, with increasing influenza-associated hospitalizations alongside declines in rhinovirus-, COVID-, and parainfluenza-associated hospitalizations.

Among adults aged 65 years and older, respiratory virus–associated hospitalizations increased substantially across December and accounted for 9.4% of all hospitalizations in the last week of December 2025, an increase from 3.7% at the beginning of the month (+154.1%). Influenza-associated hospitalizations increased more than fourfold (+316.1%), rising to 5.9% of all hospitalizations in this age group. COVID-, RSV-, and

HMPV-associated hospitalizations also increased across December (+66.4%, +155.0%, and +157.5%, respectively). Rhinovirus-associated hospitalizations decreased slightly to 0.9% of all hospitalizations, while parainfluenza-associated hospitalizations remained low and relatively stable across the month.

In this older adult population, influenza test positivity increased sharply (+169.0%). COVID, RSV, and HMPV test positivity increased across the month (+38.1%, +70.2%, and +133.9%, respectively). Parainfluenza test positivity remained stable, while rhinovirus positivity decreased slightly (-19.0 %). Overall, these findings indicate a substantial increase in respiratory virus associated hospitalizations among older adults across December, driven primarily by influenza, with additional increases also observed for COVID, RSV, and HMPV.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed January 14, 2026. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.

References

Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. The Journal of Pediatrics, 137(6), 865-870. https://doi.org/10.1067/mpd.2000.110531

Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. https://www.cdc.gov/flu/about/burden/past-seasons.html

Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. https://www.cdc.gov/surveillance/nrevss/index.html

Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm

Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. https://www.cdc.gov/rsv/research/rsv-net/dashboard.html

Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., ... Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics, 134(2), e620-e638. https://doi.org/10.1542/peds.2014-1666

Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth Eckel, Robert Mansmann, Melissa McMahon, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET), Open Forum Infectious Diseases, Volume 6, Issue 7, July 2019, ofz225, https://doi.org/10.1093/ofid/ofz225

Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. Clinical Infectious Diseases, 57(8), 1069–1077. https://doi.org/10.1093/cid/cit471

Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. Open Forum Infectious Diseases, 4(1), ofw270. https://doi.org/10.1093/ofid/ofw270

Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., ... Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. The Lancet, 390(10098), 946–958. https://doi.org/10.1016/S0140-6736(17)30938-8

Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023 Apr 6;41(15):2447-2455. https://doi.org/10.1016/j.vaccine.2023.02.038. Epub 2023 Feb 16. PMID: 36803895; PMCID: PMC9933320.

Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin Infect Dis. 2018 May 2;66(10):1511-1518. https://doi.org/10.1093/cid/cix1060. PMID: 29206909; PMCID: PMC5934309.

Truveta. (2024). Truveta's Approach to Patient Privacy. https://resources.truveta.com/patient-privacy